Recurrence score testing does not appear to benefit patients with Grade 1, progesterone receptor-positive breast cancers: An opportunity to eliminate overtreatment and decrease testing costs | Zendy

Udai S. Sibia | Zendy; Thomas J. Sanders | Zendy; Charles Mylander | Zendy; Martin Rosman | Zendy; Carol Tweed | Zendy; Lorraine Tafra | Zendy; Rubie Sue Jackson | Zendy

Open Access

Recurrence score testing does not appear to benefit patients with Grade 1, progesterone receptor-positive breast cancers: An opportunity to eliminate overtreatment and decrease testing costs

Author(s) -

Udai S. Sibia,

Thomas J. Sanders,

Charles Mylander,

Martin Rosman,

Carol Tweed,

Lorraine Tafra,

Rubie Sue Jackson

Publication year - 2021

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2021.05.005

Subject(s) - medicine , chemotherapy , breast cancer , oncology , adjuvant chemotherapy , epidemiology , gynecology , cancer

We previously described a risk prediction model (Anne Arundel Medical Center [AAMC] model) based on pathology which may eliminate the need for recurrence score (RS) testing in select early-stage breast cancers. There is a concern that patients in discordant risk prediction groups (AAMC vs. RS) may be overtreated or undertreated if RS testing were omitted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research